Work

P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.04.215

Authors: A. Hendifar, L. Rosen, A. McRee, A. Cercek, A. Basu-Mallick, D. Spigel, S. Tavazoie, E. Rowinsky, M. Szarek, F. Gonsalves, I. Kurth, C. Andreu, R. Busby, S. Spector, D. Darst, N. Lebaka, N. Bechar, M. Tavazoie, R. Wasserman, M. Fakih

Institutions: Cedars-Sinai Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University, Sarah Cannon, Tennessee Oncology, Rockefeller University, City Of Hope National Medical Center, City of Hope

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Merck, Celgene, Aeglea BioTherapeutics, Bayer Fund, Agios Pharmaceuticals, BeiGene, Apollomics, Seagen, Astellas Pharma, Ipsen, Genentech, Daiichi Sankyo Europe

OpenAlex ID: W4283784188

FWCI: 0.105

Cites:

Cited by: 1

Related to: 10